Trial
NCT05393999
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Imperial College Healthcare NHS Trust
Collaborators
Imperial College London; University of Oxford; Oxford University Hospitals NHS Trust
Condition
SARS-CoV2 Infection
Intervention
BMS-986414
Why stopped
The drug was found to be ineffective against Omicron, so the study was terminated and no patients were enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-24